Comparison between Curis Lifesciences IPO and Insomnia Media IPO.
Curis Lifesciences IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Insomnia Media IPO is a SME Bookbuilding proposed to list at NSE SME.
| Curis Lifesciences IPO | Insomnia Media IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Finaax Capital Advisors Private Limited | GYR Capital Advisors Pvt.Ltd. |
| Registrar | MUFG Intime India Pvt.Ltd. | Kfin Technologies Ltd. |
| Market Maker | RS Wealth Management Private Limited | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Curis Lifesciences IPO is up to ₹26.14 Cr whereas the issue size of the Insomnia Media IPO is up to ₹0.00 Cr. The final issue price of Curis Lifesciences IPO is ₹128.00 per share and of Insomnia Media IPO is .
| Curis Lifesciences IPO | Insomnia Media IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹120.00 per share | |
| Issue Price (Upper) | ₹128.00 per share | |
| Issue Price (Final) | ₹128.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1000 shares | |
| Fresh Issue Size | 20,42,000 shares | 48,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹26.14 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 20,42,000 shares | 48,00,000 shares |
| Issue Size Total (Amount) | up to ₹26.14 Cr | up to ₹0.00 Cr |
Curis Lifesciences IPO opens on Nov 07, 2025, while Insomnia Media IPO opens on . The closing date of Curis Lifesciences IPO and Insomnia Media IPO is Nov 11, 2025, and , respectively.
| Curis Lifesciences IPO | Insomnia Media IPO | |
|---|---|---|
| Anchor Bid Date | Nov 06, 2025 | |
| Issue Open | Nov 07, 2025 | |
| Issue Close | Nov 11, 2025 | |
| Basis Of Allotment (Tentative) | Nov 12, 2025 | |
| Initiation of Refunds (Tentative) | Nov 13, 2025 | |
| Credit of Share (Tentative) | Nov 13, 2025 | |
| Listing date (Tentative) | Nov 14, 2025 | |
| Anchor Lockin End date 1 | Dec 11, 2025 | |
| Anchor Lockin End date 2 | Feb 09, 2026 |
Curis Lifesciences IPO P/E ratio is 12.44, as compared to Insomnia Media IPO P/E ratio of .
| Curis Lifesciences IPO | Insomnia Media IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Curis Lifesciences Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 25% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 92.68 | 64.42 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 68.03 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 12.44 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹103.48 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 55.25 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.83 | 62.95 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.96 | 1.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹10.29 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 37.62 | 84.50 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Curis Lifesciences IPO Retail Individual Investors (RII) are offered 7,16,000 shares while in Insomnia Media IPO retail investors are offered 7,16,000 shares. Qualified Institutional Buyers (QIB) are offered 4,08,000 shares in Curis Lifesciences IPO and in Insomnia Media IPO.
| Curis Lifesciences IPO | Insomnia Media IPO | |
|---|---|---|
| Anchor Investor Reservation | 6,09,000 shares | |
| Market Maker Reservation | 1,08,000 shares | |
| QIB | 4,08,000 shares | |
| NII | 3,09,000 shares | |
| RII | 7,16,000 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 20,42,000 shares |
Curis Lifesciences IPO subscribed 74.39x in total, whereas Insomnia Media IPO subscribed .
| Curis Lifesciences IPO | Insomnia Media IPO | |
|---|---|---|
| QIB (times) | 96.17x | |
| NII (times) | 115.46x | |
| Big NII (times) | 142.74x | |
| Small NII (times) | 60.38x | |
| RII (times) | 44.28x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 74.39x |
